Table 4.
Neurohormonal Antagonist and Statin Prescriptions in the Subset of Patients With Medicare Part D
| Prevalent Usersa |
New Usersb |
|||||
|---|---|---|---|---|---|---|
| All Patients (n = 980) |
Patients With Prevalent HF (n = 128) |
P Value | All Patients | Patients With Prevalent HF | P Value | |
| Beta-blocker | 215 (21.9) | 59 (46.1) | <0.001c | 77 (10.1) | 17 (24.6) | <0.001c |
| ACEI or ARB | 439 (44.8) | 75 (58.6) | 0.001c | 39 (7.2) | <11d | 0.009e |
| Statin | 426 (43.5) | 65 (50.8) | 0.07c | 31 (5.6) | <11d | 0.15e |
Values are n (%).
ACEI = angiotensin-converting enzyme inhibitor; ARB = angiotensin II receptor blocker; HF = heart failure.
Prevalent users were defined by at least 1 prescription filled in the 4 months prior to lymphoma diagnosis.
New users were defined if a prescription was filled in the 6 months after lymphoma diagnosis (not including the month of lymphoma diagnosis) among those without prescriptions in the 4 months prior to lymphoma diagnosis.
P values were estimated using the chi-square test.
Cell counts with values <11 were suppressed to avoid reidentification of patients according to Surveillance, Epidemiology, and End Results and Medicare policy.
P values were estimated using the Fisher exact test.